Drug Profile
Rofecoxib - Merck & Co.
Alternative Names: Ceoxx; MK 966; Vioxx; Vioxx AcuteLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; CollaGenex Pharmaceuticals; Merck & Co; Merck Frosst
- Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Market Withdrawal Dental pain; Dysmenorrhoea; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatoid arthritis
- Discontinued Alzheimer's disease; Colorectal cancer; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Migraine; Periarthritis; Preterm labour; Sporadic adenomas
Most Recent Events
- 21 Feb 2005 An advisory committee of the FDA has recommended that the risk-benefit profile for rofecoxib supports marketing in the USA
- 11 Oct 2004 A clinical study has been added to the adverse events section
- 01 Oct 2004 Discontinued - Clinical-Phase-Unknown for Juvenile rheumatoid arthritis in Europe (PO)